Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)

Conditions: Idiopathic Pulmonary Fibrosis

First Posted Date: 2014-06-24

Last Posted Date: 2017-05-08

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02171156

Locations: 🇺🇸
1199.177.1003 Boehringer Ingelheim Investigational Site, Winter Park, Florida, United States
🇺🇸
1199.177.1022 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
🇺🇸
1199.177.1067 Boehringer Ingelheim Investigational Site, Houston, Texas, United States

and more 4 locations

BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Docetaxel
Drug: BIBW 2992

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT02171676

Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate generation I
Drug: Dabigatran etexilate generation II

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 66

Registration Number: NCT02171520

BI 10773 Administered as Oral Solution to Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-BI 10773 - oral solution

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT02172274

Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium inhalation capsules for oral inhalation

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 29

Registration Number: NCT02172326

Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1744 CL i.v.
Drug: BI 1744 CL oral

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 11

Registration Number: NCT02172157

Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 1744 CL
Drug: Placebo

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT02172131

Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: Linagliptin

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02172222

Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: Metformin

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02172248

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium bromide

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 63127

Registration Number: NCT02172482

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy